Assembly Biosciences (ASMB) shares were higher Wednesday morning after the company said that a first subject has been dosed in the phase 1a trial of ABI-6250, its hepatitis delta virus entry inhibitor candidate.
The study aims to evaluate the safety, tolerability and pharmacokinetics of the therapy across single and multiple ascending dose cohorts in participants. The study will also look at serum bile acids as a biomarker of ABI-6250's engagement of its target, which is the transporter used by the disease to infect hepatocyte.
The company said it expects to share data from the study in Q3.
Price: 12.90, Change: +0.56, Percent Change: +4.54
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。